Bioatlaincis A Clinical Stage Biopharmaceutical Company Based In San Diegocaliforniawith Operations In Beijingchinafounded In 2007Bioatla Focuses On Developing Novel Antibody Based Therapeutics For Solid Tumor Cancers Using Its Proprietary Platformsconditioned Active Biologicscaband Comprehensive Integrated Antibody Optimizationciaoa C The Company Went Public In December 2020 And Employs Around 61 Individuals Bioatla S Cab Platform Allows For The Creation Of Biologics That Activate Selectively In The Tumor Microenvironmentenhancing Therapeutic Efficacy While Minimizing Toxicity To Healthy Tissuesthe Company Has A Robust Pipelineincluding Several Candidates In Phase Ii Trials Targeting Various Cancersas Well As Preclinical Candidatesbioatla Specializes In Antibody Discoveryoptimizationand Clinical Developmentcollaborating With Partners For Preclinical Servicesits Mission Is To Improve Cancer Treatment Through Innovative Therapies That Address Unmet Medical Needs
